| Biomarker ID | 1146 |
| PMID | 23813660 |
| Year | 2013 |
| Biomarker | Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;] |
| Biomarker Basis | Mutation Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 31 PC patients and 17 patients with benign prostatic hyperplasia were included in the study. Aggressive Prostate Cancer (n=17) and Non Agressive (n=14) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | NA |
| Clinical | No |
| Remarks | PC patients were subdivided into an aggressive (Gleason Score 8 or higher, and/or T3/T4 and/or Nþ/Mþ) and non- aggressive (all others) form of PCa |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |